Ozempic vs. Wegovy: Formulations, Uses and Doses

Ozempic and Wegovy contain semaglutide, but a brand name alone no longer identifies the formulation. Both brands now include injections and tablets. Their approved uses and regimens differ, so “the same drug at a higher dose” is an incomplete comparison.^{1, 2, 3}

If you already have an Ozempic prescription, our 2 mg pen and refill guide separates the dose from total pen content and national shortage information from an individual pharmacy answer.

Start with the exact product, route and condition being treated. Then ask which labeled regimen applies and what the selected prescription will cost. A weekly injection's milligrams cannot be compared directly with a daily tablet's milligrams as a measure of strength.

Ozempic injection and tablets have separate uses

Ozempic injection is approved for adults with type 2 diabetes. Its label includes cardiovascular risk reduction in adults with established cardiovascular disease, and kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. Those outcome populations are specific; they are not a general kidney-protection claim for everyone taking semaglutide.¹

Ozempic tablets have adult type 2 diabetes and cardiovascular indications in their shared prescribing information with Rybelsus. The tablet cardiovascular indication concerns adults with type 2 diabetes at high risk for those events. Do not transfer the injection's CKD indication to tablets.² Neither Ozempic label lists weight management as an approved indication.^{1, 2}

Wegovy's indications depend on the route and age

Wegovy injection has adult weight-management and cardiovascular indications, plus weight management in adolescents aged 12 and older with obesity. Its adult liver indication is noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, stages F2–F3. That MASH indication has accelerated approval, with continued approval potentially dependent on confirmation of clinical benefit.³

Wegovy tablets have adult weight-management and cardiovascular indications. The tablet does not inherit the injection's pediatric or MASH indications. The cardiovascular indication requires established cardiovascular disease and obesity or overweight; the weight-management population has its own eligibility criteria.³

Compare doses within a formulation and indication

These are label distinctions to discuss with the prescriber, rather than a schedule for changing your own dose.

• Ozempic injection: the glycemic-control maximum is 2 mg weekly; the labeled CKD maintenance regimen is 1 mg weekly.¹
• Ozempic tablets: daily maintenance is 4 mg or 9 mg. Ozempic and Rybelsus tablets are not substitutable milligram for milligram.²
• Wegovy injection: adult weight-management labeling permits conditional escalation to 7.2 mg weekly after at least four weeks tolerating 2.4 mg when further weight reduction is clinically indicated. This is not a universal pediatric, cardiovascular or MASH regimen.³
• Wegovy tablets: the maintenance regimen is 25 mg daily.³

The earlier shorthand “Ozempic stops at 2 mg; Wegovy stops at 2.4 mg” misses current formulations and indication-specific instructions. A maximum is not a target for every patient. Our oral-versus-injectable guide covers the separate administration and evidence questions.

What the familiar weight-loss result actually studied

STEP 1 evaluated weekly injectable semaglutide 2.4 mg in adults with overweight or obesity who did not have diabetes. With lifestyle intervention, mean weight change at 68 weeks was −14.9% with semaglutide and −2.4% with placebo.⁴

That result concerns one regimen and population. It is not the result for every Ozempic or Wegovy prescription, a trial comparing the brands, or evidence that a compounded product is equivalent. Daily oral and newer injection regimens require their own evidence. For the different molecule comparison, see semaglutide versus tirzepatide.

A compounded preparation is a separate product

A pharmacy-prepared product advertised as semaglutide is not an Ozempic or Wegovy finished product. FDA does not approve compounded drugs or review their safety, effectiveness and quality before marketing.⁵ A familiar name does not establish the active ingredient, formulation, exposure or clinical equivalence of a separate preparation.

Ask for the proposed product and pharmacy label rather than accepting “just like Wegovy” as the whole explanation. Our compounded-versus-brand guide explains the distinction; a brand's label cannot settle another preparation's suitability or legal status.

Bring the exact prescription to the coverage conversation

Ask the practice to identify the product, formulation, indication and age-specific regimen before comparing cash prices or requesting benefits information. A label comparison does not establish what a particular insurance plan will cover. Check the pharmacy benefit and any authorization requirements using our insurance guide.

Once an Ozempic prescription is specified, the assistance guide explains how commercial copay offers, manufacturer cash programs and free-medicine assistance differ.

Also discuss other medicines, pregnancy plans and follow-up. Our birth-control guide explains one product-specific interaction question. These prescribing labels carry important contraindications and precautions; sharing an ingredient does not make a switch or dose conversion a do-it-yourself choice.^{1, 2, 3}

Once the prescription is clear, compare the service around it: clinician access, dispensing arrangements, recurring charges and cancellation. The provider checklist and reviews help evaluate those practical differences.